Companies press releases
Aug 16, 2022, 07:30 ET Independent Data Monitoring Committee Recommends Continuing Study with Sample Size Target of up to 350 Patients – up to Additional 230 Patients to be Enrolled No Safety Concerns Identified Topline Results Currently Expected Second Quarter Calendar 2023 CRANBURY, N.J., Aug. 16, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), […]
Jul 26, 2022, 07:30 ET Gross product sales increased 75% andPrescriptions dispensed increased 45%, over prior quarter CRANBURY, N.J., July 26, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced preliminary fourth quarter
May 17, 2022, 07:30 ET Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022 Vyleesi® – Gross product sales increased 67%, net product revenue increased 200% and prescriptions dispensed increased 20%, over the prior quarter Closed on a
May 12, 2022, 08:00 ET CRANBURY, N.J., May 12, 2022 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin” or the “Company”) (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that it has entered into a securities purchase agreement with institutional investors
May 11, 2022, 09:02 ET CRANBURY, N.J., May 11, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its
May 02, 2022, 13:02 ET Posters highlight Palatin’s ocular research and PL9643 Phase 2 clinical data CRANBURY, N.J., May 2, 2022 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two poster presentations at
Apr 21, 2022, 07:30 ET Presentation to review the role of melanocortins in the treatment of ocular disease and Phase 2 study results with Palatin’s compound PL9643 for Dry Eye Disease PL9643 Dry Eye Disease Phase 3 study ongoing – data expected 4Q 2022 CRANBURY, N.J., April 21, 2022 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”)
Discuss Ongoing PL9643 Pivotal Phase 3 Clinical Trial Webinar Monday, March 7th at 10:30 AM ET Mar 03, 2022, 07:30 ET CRANBURY, N.J., March 3, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today
Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease Read More »
– Initiated Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Expected Second Half Calendar 2022 – Approximately $47.3 Million in Cash and Cash Equivalents at December 31, 2021 – Projected Cash Runway through March 31, 2023 – Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis
Feb 10, 2022, 07:30 ET CRANBURY, N.J., Feb. 10, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2022 operating results on Tuesday, February 15, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive
